Barentz International, a prominent global specialty ingredients solution provider, has successfully acquired Anshul Life Sciences Group (“Anshul Life Sciences”), a key player in the Indian life sciences specialty chemicals distribution sector. This strategic acquisition enhances Barentz’s footprint in India, establishing a leading distribution platform in the life sciences segment and underscoring its commitment to delivering innovative solutions and technical expertise.
Anshul Life Sciences, headquartered in Mumbai, is renowned for its distribution of high-quality specialty ingredients in the pharmaceutical, food & nutraceuticals, and personal care markets. The integration of Anshul Life Sciences into Barentz’s operations is set to significantly bolster Barentz’s position in the Indian market and offer an expanded portfolio of pharmaceuticals excipients, APIs, and intermediates, alongside enhanced offerings in personal care and nutraceuticals.
Key Transaction Highlights:
- The acquisition strengthens Barentz’s market presence in India, positioning it as a leading player in the life sciences distribution sector.
- Anshul Life Sciences will enhance Barentz’s existing pharmaceuticals ingredients portfolio with premium excipients, APIs, and intermediates.
- The acquisition promises substantial growth opportunities for Barentz across the Asia Pacific region.
- Nagarajan Kailasam, CEO of Anshul Life Sciences, and his team will continue to oversee the business operations, ensuring continuity and operational excellence.
Marc Duchene, CEO APAC of Barentz, expressed enthusiasm about the acquisition, stating, “We are thrilled to welcome Anshul Life Sciences to the Barentz Group. This acquisition is a testament to our strategic focus on expanding our presence in India and the broader Asia Pacific region. It will enable us to provide our customers and principals with an enhanced portfolio of high-quality products and deepen our technical expertise. We look forward to working closely with Mr. Nagarajan and his team to drive growth and innovation.”
Nagarajan Kailasam, CEO of Anshul Life Sciences, commented, “The alignment between Barentz’s entrepreneurial spirit and our ethical standards is a key factor in this acquisition. We are eager to join forces with Barentz and leverage this opportunity to offer more comprehensive solutions to our clients in India and beyond. This partnership will enhance our capabilities and expand our international reach.”
Shardul Amarchand Mangaldas & Co. advised Barentz International on this acquisition. The team was led by Partners Roopal Kulsrestha and Neelam Pathak, along with Meghna Nachappa, Aparna R, Sandra Anil Varkey, Pranav Bajaj, and Sidharth Chamarthy.
…
Contact us at hello@lawgacy.com to feature your firm’s deals, articles, columns, or press releases.
